{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T08:44:51Z","timestamp":1782722691317,"version":"3.54.5"},"reference-count":266,"publisher":"National Institute for Health and Care Research","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["NIHR132386"],"award-info":[{"award-number":["NIHR132386"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalslibrary.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"\n Background<\/jats:title>\n Predicting a diagnosis of pre-eclampsia is based on a combination of clinical assessment of blood pressure, presence of protein in the urine, symptoms and laboratory test abnormalities. Accurately detecting pre-eclampsia is important to avoid false-positive diagnoses which could lead to unnecessary antenatal admissions and\/or preterm delivery. Four blood tests that measure the biomarkers of placental growth factor or the ratio of soluble fms-like tyrosine kinase-1 to placental growth factor are available (known as Triage, Elecsys, DELFIA Xpress, and BRAHMS Kryptor tests). Abnormal measurements of these biomarkers can be used as an aid to predict a diagnosis of pre-eclampsia and maternal and fetal outcomes.<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n To evaluate the test accuracy, clinical effectiveness and cost-effectiveness of placental growth factor -based tests used in conjunction with standard clinical assessment for predicting pre-eclampsia and maternal and fetal outcomes in pregnant women who are referred to secondary care with suspected pre-eclampsia in weeks 20\u201337 of pregnancy.<\/jats:p>\n <\/jats:sec>\n \n Data sources and methods<\/jats:title>\n A systematic review of the diagnostic\/prognostic accuracy and clinical effectiveness of placental growth factor-based tests with standard clinical assessment. Database included MEDical Literature Analysis and Retrieval System, Excerpta Medica dataBASE and Cochrane Library. Other sources searched included relevant conference proceedings and websites, grey literature and research in progress. The most recent date of searching was 18 March 2021. An independent economic analysis was conducted using a decision tree model. The model includes short-term costs and quality-adjusted life-years for the management of women, maternal and neonatal outcomes and long-term outcomes for severe neonatal complications. The model compared the use of the test alongside standard clinical assessment to standard clinical assessment only. Two different estimates of standard clinical assessment were included, from the INSPIRE study and from National Institute of Health and Care Excellence Diagnostic Guidance 23.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Seventeen studies were included in the systematic review. Two large, randomised trials provided the best available evidence to inform the economic model: The PARROT trial (Triage test) and the INSPIRE trial (Elecsys test). When used as rule-out tests for pre-eclampsia (with neonatal outcomes included), all four tests produced higher quality-adjusted life-years and higher costs than both types of standard clinical assessment. The incremental cost per quality-adjusted life-year ranged from \u00a3637 (DELFIA test vs. standard clinical assessment from INSPIRE) to \u00a347,393 (Triage test vs. standard clinical assessment from diagnostics guidance 23) per quality-adjusted life-year. Incremental costs and quality-adjusted life-years were always very small, with incremental costs always less than the cost of the test and incremental quality-adjusted life-years always <\u20050.006.<\/jats:p>\n <\/jats:sec>\n \n Limitations<\/jats:title>\n Although the evidence for placental growth factor-based tests is advancing, there remains uncertainty for key parameters, such as diagnostic sensitivity and specificity. This particularly affects the Elecsys test.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Despite uncertainties from lack of data, and heterogeneity across studies, the use of placental growth factor-based tests to rule out and rule in pre-eclampsia has the potential to provide improved outcomes at reduced cost when compared with standard clinical assessment.<\/jats:p>\n <\/jats:sec>\n \n Future work<\/jats:title>\n Future research priorities include more rigorous evaluation of the DELFIA and BRAHMS placental growth factor-based tests, more evidence for Triage and Elecsys as rule-in tests, and greater focus on Black, and Asian and Mixed ethnicity groups.<\/jats:p>\n <\/jats:sec>\n \n Study registration<\/jats:title>\n This study is registered as PROSPERO CRD42020227085.<\/jats:p>\n <\/jats:sec>\n \n Funding<\/jats:title>\n \n This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: NIHR132386) and is published in full in\n Health Technology Assessment<\/jats:italic>\n ; Vol. 30, No. 54. See the NIHR Funding and Awards website for further award information.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3310\/hdst9104","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T10:34:39Z","timestamp":1755599679000},"page":"1-160","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Placental growth factor (PLGF)-based testing to help diagnose suspected pre-eclampsia: a systematic review and economic evaluation"],"prefix":"10.3310","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1682-4330","authenticated-orcid":true,"given":"Jonathan","family":"Shepherd","sequence":"first","affiliation":[{"name":"Southampton Health Technology Assessments Centre (SHTAC), University of Southampton, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2005-0497","authenticated-orcid":true,"given":"Geoff","family":"Frampton","sequence":"additional","affiliation":[{"name":"Southampton Health Technology Assessments Centre (SHTAC), University of Southampton, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7730-668X","authenticated-orcid":true,"given":"Ben","family":"Kearns","sequence":"additional","affiliation":[{"name":"Decision Support Unit, Sheffield Centre for Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8631-6465","authenticated-orcid":true,"given":"Karen","family":"Pickett","sequence":"additional","affiliation":[{"name":"Southampton Health Technology Assessments Centre (SHTAC), University of Southampton, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8464-4513","authenticated-orcid":true,"given":"In\u00eas","family":"Souto-Ribeiro","sequence":"additional","affiliation":[{"name":"Southampton Health Technology Assessments Centre (SHTAC), University of Southampton, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9324-1617","authenticated-orcid":true,"given":"Allan J","family":"Wailoo","sequence":"additional","affiliation":[{"name":"Decision Support Unit, Sheffield Centre for Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4587-9149","authenticated-orcid":true,"given":"Lois","family":"Woods","sequence":"additional","affiliation":[{"name":"Southampton Health Technology Assessments Centre (SHTAC), University of Southampton, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0318-7670","authenticated-orcid":true,"given":"Keith","family":"Cooper","sequence":"additional","affiliation":[{"name":"Southampton Health Technology Assessments Centre (SHTAC), University of Southampton, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5962-0648","authenticated-orcid":true,"given":"Lorna","family":"Hazell","sequence":"additional","affiliation":[{"name":"Southampton Health Technology Assessments Centre (SHTAC), University of Southampton, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2552-5260","authenticated-orcid":true,"given":"Abdullah","family":"Pandor","sequence":"additional","affiliation":[{"name":"Decision Support Unit, Sheffield Centre for Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6475-8046","authenticated-orcid":true,"given":"David A","family":"Scott","sequence":"additional","affiliation":[{"name":"Southampton Health Technology Assessments Centre (SHTAC), University of Southampton, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2026,6]]},"reference":[{"key":"key2026062913240900_ref2-bib2","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.preghy.2018.05.004","article-title":"The hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management recommendations for international practice","volume":"13","author":"Brown","year":"2018","journal-title":"Pregnancy Hypertens"},{"key":"key2026062913240900_ref3-bib3","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1097\/AOG.0000000000003891","article-title":"Gestational hypertension and preeclampsia: ACOG Practice Bulletin, number 222","volume":"135","author":"American College of Obstetricians Gynecologists","year":"2020","journal-title":"Obstet Gynecol"},{"key":"key2026062913240900_ref4-bib4","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1161\/HYPERTENSIONAHA.117.10318","article-title":"Assessment of the full PIERS risk prediction model in women with early-onset preeclampsia","volume":"71","author":"Ukah","year":"2018","journal-title":"Hypertension"},{"key":"key2026062913240900_ref5-bib5","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12916-017-0827-3","article-title":"Prediction of complications in early-onset pre-eclampsia (PREP): development and external multinational validation of prognostic models","volume":"15","author":"Thangaratinam","year":"2017","journal-title":"BMC Med"},{"key":"key2026062913240900_ref6-bib6","first-page":"1","article-title":"Placental growth factor (alone or in combination with soluble fms-like tyrosine kinase 1) as an aid to the assessment of women with suspected pre-eclampsia: systematic review and economic analysis","volume":"20","author":"Frampton","year":"2016","journal-title":"Health Technol Assess"},{"key":"key2026062913240900_ref8-bib8","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"key2026062913240900_ref10-bib10","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/s41440-021-00629-x","article-title":"Short-term prediction of preeclampsia using the sFlt-1\/PlGF ratio: a subanalysis of pregnant Japanese women from the PROGNOSIS Asia study","volume":"44","author":"Ohkuchi","year":"2021","journal-title":"Hypertens Res"},{"key":"key2026062913240900_ref11-bib11","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.preghy.2013.04.023","article-title":"OP007. PLGF in combination with other commonly utilised tests and other biomarkers for predicting need for delivery for pre-eclampsia within 14 days in women presenting prior to 35 weeks\u2019 gestation","volume":"3","author":"Chappell","year":"2013","journal-title":"Pregnancy Hypertens"},{"key":"key2026062913240900_ref12-bib12","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.preghy.2012.04.101","article-title":"Plasma placental growth factor (PLGF) measurement in women presenting with suspected pre-eclampsia: the pelican study","volume":"2","author":"Chappell","year":"2012","journal-title":"Pregnancy Hypertens"},{"key":"key2026062913240900_ref13-bib13","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann Intern Med"},{"key":"key2026062913240900_ref14-bib14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.preghy.2020.10.005","article-title":"Placental growth factor measurements in the assessment of women with suspected preeclampsia: a stratified analysis of the PARROT trial","volume":"23","author":"Duhig","year":"2021","journal-title":"Pregnancy Hypertens"},{"key":"key2026062913240900_ref15-bib15","doi-asserted-by":"crossref","first-page":"e23740","DOI":"10.1002\/jcla.23740","article-title":"Predictive values of various serum biomarkers in women with suspected preeclampsia: a prospective study","volume":"35","author":"Wang","year":"2021","journal-title":"J Clin Lab Anal"},{"key":"key2026062913240900_ref16-bib16","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.preghy.2020.11.010","article-title":"Real life outpatient biomarker use in management of hypertensive pregnancies in third trimester in a low resource SeTting: ROBUST study","volume":"23","author":"Soundararajan","year":"2021","journal-title":"Pregnancy Hypertens"},{"key":"key2026062913240900_ref17-bib17","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/1471-0528.15855","article-title":"Evaluation of the impact of revealed placental growth factor testing in women with suspected preeclampsia: a stratified analysis of the PARROT trial","volume":"126","author":"Duhig","year":"2019","journal-title":"BJOG"},{"key":"key2026062913240900_ref18-bib18","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1111\/1471-0528.15855","article-title":"Placental growth factor measurements in the assessment of women with suspected pre-eclampsia; a stratified analysis of the PARROT trial data","volume":"126","author":"Duhig","year":"2019","journal-title":"BJOG"},{"key":"key2026062913240900_ref19-bib19","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/S0140-6736(18)33212-4","article-title":"Placental growth factor testing to assess women with suspected pre-eclampsia: a multicentre, pragmatic, stepped-wedge cluster-randomised controlled trial","volume":"393","author":"Duhig","year":"2019","journal-title":"Lancet"},{"key":"key2026062913240900_ref20-bib20","doi-asserted-by":"crossref","first-page":"S269","DOI":"10.1016\/j.ajog.2012.10.802","article-title":"Plasma placental growth factor (PlGF) in the diagnosis of women with pre-eclampsia requiring delivery within 14 days: The PELICAN study","volume":"208","author":"Chappell","year":"2013","journal-title":"Am J Obstet Gynecol"},{"key":"key2026062913240900_ref21-bib21","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/AOG.0000000000001508","article-title":"Diagnostic biomarkers in women with suspected preeclampsia in a prospective multicenter study","volume":"128","author":"Duckworth","year":"2016","journal-title":"Obstet Gynecol"},{"key":"key2026062913240900_ref23-bib23","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.kint.2015.10.012","article-title":"Diagnostic and predictive biomarkers for pre-eclampsia in patients with established hypertension and chronic kidney disease","volume":"89","author":"Bramham","year":"2016","journal-title":"Kidney Int"},{"key":"key2026062913240900_ref24-bib24","first-page":"204","article-title":"Placental growth factor predicts time to delivery in women with signs or symptoms of early preterm preeclampsia: a prospective multicenter study","volume":"40","author":"Barton","year":"2020","journal-title":"Obstet Gynecol Surv"},{"key":"key2026062913240900_ref25-bib25","doi-asserted-by":"crossref","first-page":"259.e1","DOI":"10.1016\/j.ajog.2019.09.003","article-title":"Placental growth factor predicts time to delivery in women with signs or symptoms of early preterm preeclampsia: a prospective multicenter study","volume":"222","author":"Barton","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"key2026062913240900_ref26-bib26","volume-title":"Pre-Eclampsia Triage by Rapid Assay of Novel Biomarkers of Placental Function and Maternal Adaptation (PETRA) (Confidential Company Submission)","author":"Sibai","year":"2015"},{"key":"key2026062913240900_ref27-bib27","doi-asserted-by":"crossref","first-page":"S264","DOI":"10.1016\/j.ajog.2015.10.525","article-title":"Diagnostic and prognostic performance of placenta growth factor (PLGF) in women with signs or symptoms of early preterm preeclampsia","volume":"214","author":"Woelkers","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"key2026062913240900_ref28-bib28","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.ajog.2015.10.060","article-title":"Placenta Growth Factor (PLGF) predicts time to delivery in women with signs or symptoms of early preterm preeclampsia","volume":"214","author":"Woelkers","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"key2026062913240900_ref29-bib29","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/uog.19051","article-title":"Comparison of three commercially available placental growth factor-based tests in women with suspected preterm pre-eclampsia: the COMPARE study","volume":"53","author":"McCarthy","year":"2019","journal-title":"Ultrasound Obstet Gynecol"},{"key":"key2026062913240900_ref30-bib30","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.preghy.2018.03.013","article-title":"Placental growth factor informed management of suspected pre-eclampsia or fetal growth restriction: the MAPPLE cohort study","volume":"14","author":"Sharp","year":"2018","journal-title":"Pregnancy Hypertens"},{"key":"key2026062913240900_ref31-bib31","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.preghy.2018.03.007","article-title":"A clinical evaluation of placental growth factor in routine practice in high-risk women presenting with suspected pre-eclampsia and\/or fetal growth restriction","volume":"14","author":"Ormesher","year":"2018","journal-title":"Pregnancy Hypertens"},{"key":"key2026062913240900_ref32-bib32","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/HYPERTENSIONAHA.119.12739","article-title":"Randomized interventional study on prediction of preeclampsia\/eclampsia in women with suspected preeclampsia: INSPIRE","volume":"74","author":"Cerdeira","year":"2019","journal-title":"Hypertension"},{"key":"key2026062913240900_ref33-bib33","first-page":"31297","article-title":"Performance of soluble fms-like tyrosine kinase-1-to-placental growth factor ratio of \u226585 for ruling in preeclampsia within 4 weeks","volume":"15","author":"Cerdeira","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"key2026062913240900_ref34-bib34","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/uog.19178","article-title":"Soluble fms-like tyrosine kinase-1 to placental growth factor ratio: ruling out pre-eclampsia for up to 4 weeks and value of retesting","volume":"53","author":"Zeisler","year":"2019","journal-title":"Ultrasound Obstet Gynecol"},{"key":"key2026062913240900_ref35-bib35","first-page":"S176","article-title":"Angiogenic markers in preeclampsia: from clinical evidence to implementation in routine","volume":"55","author":"Verlohren","year":"2017","journal-title":"Clin Chem Lab Med"},{"key":"key2026062913240900_ref36-bib36","first-page":"243","article-title":"Novel diagnostic tools for prediction and diagnosis of preeclampsia","volume":"45","author":"Stepan","year":"2017","journal-title":"J Perinat Med"},{"key":"key2026062913240900_ref37-bib37","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1414838","article-title":"Predictive value of the sFlt-1: PlGF ratio in women with suspected preeclampsia","volume":"374","author":"Zeisler","year":"2016","journal-title":"N Engl J Med"},{"key":"key2026062913240900_ref38-bib38","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.preghy.2016.08.009","article-title":"The sFlt-1\/PLGF ratio can rule out preeclampsia for up to four weeks in women with suspected preeclampsia","volume":"6","author":"Verlohren","year":"2016","journal-title":"Pregnancy Hypertens"},{"key":"key2026062913240900_ref39-bib39","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/AOG.0000000000001525","article-title":"Soluble fms-like tyrosine kinase-1-to-placental growth factor ratio and time to delivery in women with suspected preeclampsia","volume":"128","author":"Zeisler","year":"2016","journal-title":"Obstet Gynecol"},{"key":"key2026062913240900_ref41-bib41","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1161\/HYPERTENSIONAHA.119.12760","article-title":"Short-term prediction of adverse outcomes using the sFlt-1 (soluble fms-like tyrosine kinase 1)\/PlGF (placental growth factor) ratio in Asian women with suspected preeclampsia","volume":"74","author":"Bian","year":"2019","journal-title":"Hypertension"},{"key":"key2026062913240900_ref42-bib42","first-page":"13","article-title":"PROGNOSIS Asia: prediction of short-term outcome in pregnant women with suspected preeclampsia study using the sFlt-1\/PlGF ratio in an Asian population","volume":"125","author":"Bian","year":"2018","journal-title":"BJOG"},{"key":"key2026062913240900_ref43-bib43","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.preghy.2018.05.008","article-title":"Angiogenic biomarkers in triage and risk for preeclampsia with severe features","volume":"13","author":"Rana","year":"2018","journal-title":"Pregnancy Hypertens"},{"key":"key2026062913240900_ref44-bib44","doi-asserted-by":"crossref","first-page":"89.e1","DOI":"10.1016\/j.ajog.2016.01.168","article-title":"Sequential plasma angiogenic factors levels in women with suspected preeclampsia","volume":"215","author":"Baltajian","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"key2026062913240900_ref45-bib45","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3109\/10641955.2016.1148162","article-title":"KRYPTOR-automated angiogenic factor assays and risk of preeclampsia-related adverse outcomes","volume":"35","author":"Salahuddin","year":"2016","journal-title":"Hypertens Pregnancy"},{"key":"key2026062913240900_ref46-bib46","doi-asserted-by":"crossref","first-page":"e0156013","DOI":"10.1371\/journal.pone.0156013","article-title":"Influence of the sFlt-1\/PlGF ratio on clinical decision-making in women with suspected preeclampsia","volume":"11","author":"Klein","year":"2016","journal-title":"PLOS ONE"},{"key":"key2026062913240900_ref47-bib47","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1161\/HYPERTENSIONAHA.120.14957","article-title":"The prognostic value of angiogenic markers in twin pregnancies to predict delivery due to maternal complications of preeclampsia","volume":"76","author":"Binder","year":"2020","journal-title":"Hypertension"},{"key":"key2026062913240900_ref48-bib48","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.preghy.2019.08.092","article-title":"Retrospective study of the diagnostic usefulness of sFlt-1\/PlGF ratio as a predictor of developing preeclampsia among high risk pregnancies in a clinical setting in Denmark","volume":"17","author":"Andersen","year":"2019","journal-title":"Pregnancy Hypertens"},{"key":"key2026062913240900_ref49-bib49","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.preghy.2021.12.008","article-title":"Rule-in and rule-out of pre-eclampsia using DELFIA Xpress PlGF 1-2-3 and sFlt-1: PlGF ratio","volume":"27","author":"Bremner","year":"2022","journal-title":"Pregnancy Hypertens"},{"key":"key2026062913240900_ref50-bib50","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1515\/cclm-2013-0901","article-title":"New biomarkers in diagnosis of early onset preeclampsia and imminent delivery prognosis","volume":"52","author":"Alvarez-Fernandez","year":"2014","journal-title":"Clin Chem Lab Med"},{"key":"key2026062913240900_ref51-bib51","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.cca.2016.10.033","article-title":"N-terminal pro B-type natriuretic peptide and angiogenic biomarkers in the prognosis of adverse outcomes in women with suspected preeclampsia","volume":"463","author":"Alvarez-Fernandez","year":"2016","journal-title":"Clin Chim Acta"},{"key":"key2026062913240900_ref52-bib52","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1515\/cclm-2019-0939","article-title":"A more accurate prediction to rule in and rule out pre-eclampsia using the sFlt-1\/PlGF ratio and NT-proBNP as biomarkers","volume":"58","author":"Lafuente-Ganuza","year":"2020","journal-title":"Clin Chem Lab Med"},{"key":"key2026062913240900_ref53-bib53","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1161\/HYPERTENSIONAHA.116.08547","article-title":"Diagnostic performance of placental growth factor in women with suspected preeclampsia attending antenatal facilities in Maputo, Mozambique","volume":"69","author":"Ukah","year":"2017","journal-title":"Hypertension"},{"key":"key2026062913240900_ref54-bib54","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.preghy.2017.12.005","article-title":"Early diagnosis of preeclampsia using placental growth factor: an operational pilot study in Maputo, Mozambique","volume":"11","author":"Manriquez Rocha","year":"2018","journal-title":"Pregnancy Hypertens"},{"key":"key2026062913240900_ref55-bib55","doi-asserted-by":"crossref","first-page":"e021376","DOI":"10.1161\/JAHA.120.021376","article-title":"Decision threshold for Kryptor sFlt-1\/PlGF ratio in women with suspected preeclampsia: retrospective study in a routine clinical setting","volume":"10","author":"Andersen","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"key2026062913240900_ref56-bib56","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejogrb.2016.02.013","article-title":"The sFlt-1\/PlGF ratio associates with prolongation and adverse outcome of pregnancy in women with (suspected) preeclampsia: analysis of a high-risk cohort","volume":"199","author":"Saleh","year":"2016","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"key2026062913240900_ref57-bib57","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.preghy.2014.02.001","article-title":"The classification, diagnosis and management of the hypertensive disorders of pregnancy: a revised statement from the ISSHP","volume":"4","author":"Tranquilli","year":"2014","journal-title":"Pregnancy Hypertens"},{"key":"key2026062913240900_ref59-bib59","volume-title":"The Investigation and Management of the Small-for-Gestational\u2013Age Fetus. RCOG Green-Top Guideline; No. 31","author":"Robson","year":"2013"},{"key":"key2026062913240900_ref60-bib60","first-page":"1122","article-title":"Hypertension in pregnancy: report of the American College of Obstetricians and Gynecologists\u2019 Task Force on Hypertension in Pregnancy","volume":"122","author":"American College of Obstetricians and Gynecologists\u2019 Task Force on Hypertension in Pregnancy","year":"2013","journal-title":"Obstet Gynecol"},{"key":"key2026062913240900_ref61-bib61","doi-asserted-by":"crossref","first-page":"ix","DOI":"10.3109\/10641950109152635","article-title":"The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP)","volume":"20","author":"Brown","year":"2001","journal-title":"Hypertens Pregnancy"},{"key":"key2026062913240900_ref62-bib62","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0029-7844(01)01747-1","article-title":"ACOG practice bulletin no. 33: diagnosis and management of preeclampsia and eclampsia","volume":"99","author":"ACOG Committee on Practice Bulletins \u2013 Obstetrics","year":"2002","journal-title":"Obstet Gynecol"},{"key":"key2026062913240900_ref63-bib63","first-page":"1","article-title":"ACOG practice bulletin no. 202 summary: gestational hypertension and preeclampsia","volume":"133","year":"2019","journal-title":"Obstet Gynecol"},{"key":"key2026062913240900_ref64-bib64","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/1471-0528.16518","article-title":"A prospective study of placental growth factor in twin pregnancy and development of a dichorionic twin pregnancy specific reference range","volume":"128","author":"Hayes-Ryan","year":"2021","journal-title":"BJOG"},{"key":"key2026062913240900_ref65-bib65","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/HYPERTENSIONAHA.112.195065","article-title":"Circulating angiogenic factors and risk of adverse maternal and perinatal outcomes in twin pregnancies with suspected preeclampsia","volume":"60","author":"Rana","year":"2012","journal-title":"Hypertension"},{"key":"key2026062913240900_ref66-bib66","doi-asserted-by":"crossref","first-page":"636.e1","DOI":"10.1016\/j.ajog.2014.11.035","article-title":"Maternal circulating angiogenic factors in twin and singleton pregnancies","volume":"212","author":"Faupel-Badger","year":"2015","journal-title":"Am J Obstet Gynecol"},{"key":"key2026062913240900_ref67-bib67","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/uog.14760","article-title":"Maternal serum sFlt-1\/PlGF ratio in twin pregnancies with and without pre-eclampsia in comparison with singleton pregnancies","volume":"45","author":"Dr\u00f6ge","year":"2015","journal-title":"Ultrasound Obstet Gynecol"},{"key":"key2026062913240900_ref68-bib68","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.preghy.2018.03.014","article-title":"The predictive value of the sFlt-1\/PlGF ratio on short-term absence of preeclampsia and maternal and fetal or neonatal complications in twin pregnancies","volume":"14","author":"Saleh","year":"2018","journal-title":"Pregnancy Hypertens"},{"key":"key2026062913240900_ref69-bib69","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ajog.2021.11.1345","article-title":"Ruling out preeclampsia in the next 4 weeks using a soluble fms-like tyrosine kinase 1\/placental growth factor ratio \u226438: secondary analysis of the Interventional Study on Prediction of Preeclampsia\/Eclampsia in Women with Suspected Preeclampsia","volume":"226","author":"Cerdeira","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"key2026062913240900_ref71-bib71","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.preghy.2019.06.004","article-title":"Inter-manufacturer comparison of automated immunoassays for the measurement of soluble FMS-like tyrosine kinase-1 and placental growth factor","volume":"17","author":"Cheng","year":"2019","journal-title":"Pregnancy Hypertens"},{"key":"key2026062913240900_ref72-bib72","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.preghy.2020.04.005","article-title":"Rule-in thresholds for DELFIA Xpress PlGF 1-2-3 test for suspected pre-eclampsia","volume":"21","author":"Giblin","year":"2020","journal-title":"Pregnancy Hypertens"},{"key":"key2026062913240900_ref73-bib73","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1161\/HYPERTENSIONAHA.119.13997","article-title":"Angiogenic marker prognostic models in pregnant women with hypertension","volume":"75","author":"Perry","year":"2020","journal-title":"Hypertension"},{"key":"key2026062913240900_ref74-bib74","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198529446.001.0001","volume-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"2005"},{"key":"key2026062913240900_ref75-bib75","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta8360","article-title":"Review of guidelines for good practice in decision-analytic modelling in health technology assessment","volume":"8","author":"Philips","year":"2004","journal-title":"Health Technol Assess"},{"key":"key2026062913240900_ref77-bib77","doi-asserted-by":"crossref","first-page":"S503","DOI":"10.1016\/j.ajog.2019.11.811","article-title":"795: Assessment of costs and patient satisfaction of standard versus biomarker evaluation of late preterm preeclampsia","volume":"222","author":"Adami","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"key2026062913240900_ref78-bib78","first-page":"85","article-title":"The sFlt-1\/placental growth factor (PlGF) ratio: experience in implementing a new test","volume":"59","author":"Brennecke","year":"2019","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"key2026062913240900_ref79-bib79","doi-asserted-by":"crossref","first-page":"A923","DOI":"10.1016\/j.jval.2017.08.2884","article-title":"Preliminary results of benefits study \u2013 Brazilian economic evaluation of SFLT-1\/PLGF test for preeclampsia prediction and diagnosis: private perspective","volume":"20","author":"Cordioli","year":"2017","journal-title":"Value Health"},{"key":"key2026062913240900_ref80-bib80","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/1471-0528.15855","article-title":"Placental growth factor testing for suspected preeclampsia: a cost-minimisation analysis","volume":"126","author":"Duhig","year":"2019","journal-title":"BJOG"},{"key":"key2026062913240900_ref81-bib81","doi-asserted-by":"crossref","first-page":"A864","DOI":"10.1016\/j.jval.2017.08.2512","article-title":"Economic benefits of SFLT-1\/PLGF testing for preeclampsia in Colombia: a five year budget impact analysis","volume":"20","author":"Duva","year":"2017","journal-title":"Value Health"},{"key":"key2026062913240900_ref82-bib82","first-page":"S46","article-title":"Analisis de Impacto Presupuestario Sobre La Incorporacion del Cociente Sflt-1\/Plgf Para Predecir el Riesgo de Preeclampsia en el Sanatorio Finochietto de Argentina","volume":"19","author":"Garay","year":"2019","journal-title":"Value Health Reg Issues"},{"key":"key2026062913240900_ref83-bib83","first-page":"S47","article-title":"Analisis de Impacto Presupuestario Sobre la Incorporacion del Cociente Sflt-1\/Plgf Para Predecir el Riesgo de Preeclampsia en el Sistema de Salud Publico de Mendoza, Argentina","volume":"19","author":"Garay","year":"2019","journal-title":"Value Health Reg Issues"},{"key":"key2026062913240900_ref84-bib84","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.vhri.2019.08.055","article-title":"Analisis de Impacto Presupuestario Sobre la Incorporacion del Cociente Sflt-1\/Plgf Para Predecir el Riesgo de Preeclampsia en la Cobertura de las Obras Sociales Nacionales de Argentina","volume":"19","author":"Garay","year":"2019","journal-title":"Value Health Reg Issues"},{"key":"key2026062913240900_ref85-bib85","doi-asserted-by":"crossref","first-page":"S186","DOI":"10.1016\/j.jval.2019.04.823","article-title":"Pih23 budget impact analysis of Sflt-1\/Plgf ratio to help rule-out pre-eclampsia in women presenting with suspected pre-eclampsia in the private healthcare system in Brazil","volume":"22","author":"Ho","year":"2019","journal-title":"Value Health"},{"key":"key2026062913240900_ref86-bib86","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1080\/13696998.2020.1775619","article-title":"Preeclampsia in Switzerland: a cost analysis in two hospitals","volume":"23","author":"Hodel","year":"2020","journal-title":"J Med Econ"},{"key":"key2026062913240900_ref87-bib87","volume-title":"Assistance Publique: H\u00f4pitaux de Paris \u2013 Preeclampsia Ratio (sFlt-1\/PlGF) (PRECOG)","author":"ClinicalTrials.gov","year":"2017"},{"key":"key2026062913240900_ref88-bib88","first-page":"S376","article-title":"The SFLT-1\/PLGF ratio test in preeclampsia: an economic assessment for Italy","volume":"55","author":"Paolini","year":"2017","journal-title":"Clin Chem Lab Med"},{"key":"key2026062913240900_ref89-bib89","doi-asserted-by":"crossref","first-page":"S254","DOI":"10.1016\/j.jval.2018.09.1519","article-title":"Economic evaluation of the burden of preeclampsia within an Italian Regional Health Service","volume":"21","author":"Speranza","year":"2018","journal-title":"Value Health"},{"key":"key2026062913240900_ref90-bib90","doi-asserted-by":"crossref","first-page":"A688","DOI":"10.1016\/j.jval.2016.09.1960","article-title":"Investigating the economic impact of Sflt-1\/PLGF ratio as a predictive test in women with suspected preeclampsia in Italy","volume":"19","author":"Paolini","year":"2016","journal-title":"Value Health"},{"key":"key2026062913240900_ref91-bib91","doi-asserted-by":"crossref","first-page":"e0164276","DOI":"10.1371\/journal.pone.0164276","article-title":"Placental growth factor (PlGF) in women with suspected pre-eclampsia prior to 35 weeks\u2019 gestation: a budget impact analysis","volume":"11","author":"Duckworth","year":"2016","journal-title":"PLOS ONE"},{"key":"key2026062913240900_ref92-bib92","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1111\/1471-0528.15855","article-title":"Placental growth factor testing for suspected pre-eclampsia: a cost-effectiveness analysis","volume":"126","author":"Duhig","year":"2019","journal-title":"BJOG"},{"key":"key2026062913240900_ref93-bib93","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.preghy.2018.04.014","article-title":"Economic evaluation of sFlt-1\/PLGF ratio test in pre-eclampsia prediction and diagnosis in two Brazilian hospitals","volume":"13","author":"Figueira","year":"2018","journal-title":"Pregnancy Hypertens"},{"key":"key2026062913240900_ref94-bib94","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1080\/14767058.2016.1242122","article-title":"Budget impact analysis of sFlt-1\/PlGF ratio as prediction test in Italian women with suspected preeclampsia","volume":"30","author":"Frusca","year":"2017","journal-title":"J Matern Fetal Neonatal Med"},{"key":"key2026062913240900_ref95-bib95","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1080\/14767058.2019.1624718","article-title":"Management of pregnancy blood pressure increase in the emergency room: role of PlGF-based biochemical markers and relative economic impact","volume":"34","author":"Giardini","year":"2019","journal-title":"J Matern Fetal Neonatal Med"},{"key":"key2026062913240900_ref96-bib96","doi-asserted-by":"crossref","first-page":"4096847","DOI":"10.1155\/2019\/4096847","article-title":"sFlt-1\/PlGF ratio as a predictive marker in women with suspected preeclampsia: an economic evaluation from a Swiss perspective","volume":"2019","author":"Hodel","year":"2019","journal-title":"Dis Markers"},{"key":"key2026062913240900_ref97-bib97","volume-title":"Safety, Clinical Effectiveness, Predictive Accuracy and Cost Effectiveness of Blood Based Tests for Women with Suspected Preeclampsia: A Health Technology Assessment","author":"Myrhaug","year":"2020"},{"key":"key2026062913240900_ref98-bib98","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1186\/s12913-018-3406-1","article-title":"Economic assessment of the use of the sFlt-1\/PLGF ratio test to predict preeclampsia in Germany","volume":"18","author":"Schlembach","year":"2018","journal-title":"BMC Health Serv Res"},{"key":"key2026062913240900_ref99-bib99","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/uog.15997","article-title":"sFlt-1\/PlGF ratio test for pre-eclampsia: an economic assessment for the UK","volume":"48","author":"Vatish","year":"2016","journal-title":"Ultrasound Obstet Gynecol"},{"key":"key2026062913240900_ref100-bib100","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jcrc.2017.09.034","article-title":"Health-related quality of life after obstetric intensive care admission: comparison with the general population","volume":"43","author":"Sepp\u00e4nen","year":"2018","journal-title":"J Crit Care"},{"key":"key2026062913240900_ref101-bib101","doi-asserted-by":"crossref","first-page":"e0155299","DOI":"10.1371\/journal.pone.0155299","article-title":"Electroencephalography in normotensive and hypertensive pregnancies and subsequent quality of life","volume":"11","author":"Brusse","year":"2016","journal-title":"PLOS ONE"},{"key":"key2026062913240900_ref102-bib102","first-page":"8833","article-title":"Music therapy improves pregnancy-induced hypertension treatment efficacy","volume":"9","author":"Cao","year":"2016","journal-title":"Int J Clin Exp Med"},{"key":"key2026062913240900_ref103-bib103","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1111\/aogs.13624","article-title":"Health-related quality of life during pregnancy: a repeated measures study of changes from the first trimester to birth","volume":"98","author":"Morin","year":"2019","journal-title":"Acta Obstet Gynecol Scand"},{"key":"key2026062913240900_ref104-bib104","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejogrb.2014.11.038","article-title":"Determinants of health-related quality of life in the postpartum period after obstetric complications","volume":"185","author":"Prick","year":"2015","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"key2026062913240900_ref105-bib105","doi-asserted-by":"crossref","first-page":"S381","DOI":"10.1016\/j.ajog.2016.11.382","article-title":"Antiphospholipid antibody screening following pregnancy with IUGR or preeclampsia: a cost effectiveness analysis","volume":"216","author":"Aviram","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"key2026062913240900_ref106-bib106","first-page":"2001","article-title":"The relationship to maternal age and pregnancy outcome","volume":"43","author":"Crnogorac","year":"2015","journal-title":"J Perinat Med Conf"},{"key":"key2026062913240900_ref107-bib107","first-page":"S34","article-title":"Role of magnesium sulfate in therapy of preeclampsia and postoperative pain management","volume":"35","author":"Die-Mostic","year":"2018","journal-title":"Int J Obstet Anesth"},{"key":"key2026062913240900_ref108-bib108","doi-asserted-by":"crossref","first-page":"S365","DOI":"10.1016\/j.ajog.2019.11.585","article-title":"569: Alternate dosing for magnesium in obese preeclamptic women: a cost-effectiveness analysis","volume":"222","author":"Hersh","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"key2026062913240900_ref109-bib109","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.ajog.2018.11.023","article-title":"20: Induction of labor versus expectant management at 39 weeks: a cost-effectiveness analysis","volume":"220","author":"Hersh","year":"2019","journal-title":"Am J Obstet Gynecol"},{"key":"key2026062913240900_ref110-bib110","first-page":"S237","article-title":"A cost-effectiveness analysis on the optimal timing of delivery for women with preeclampsia without severe features","volume":"214","author":"Lai","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"key2026062913240900_ref111-bib111","doi-asserted-by":"crossref","first-page":"S406","DOI":"10.1016\/j.ajog.2015.10.827","article-title":"Tight versus less tight control of blood pressure in pregnant women with chronic hypertension \u2013 a cost-effective analysis","volume":"214","author":"Merrill","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"key2026062913240900_ref112-bib112","doi-asserted-by":"crossref","first-page":"37S","DOI":"10.1097\/01.AOG.0000514328.17289.43","article-title":"Adverse neonatal outcomes among women with hypertensive disorders of pregnancy","volume":"129","author":"Rincon","year":"2017","journal-title":"Obstet Gynecol"},{"key":"key2026062913240900_ref113-bib113","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.1016\/j.ajog.2019.11.225","article-title":"209: Low-dose versus medium-dose aspirin for preeclampsia prevention in pregnancy: a cost-effectiveness analysis","volume":"222","author":"Saito","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"key2026062913240900_ref114-bib114","doi-asserted-by":"crossref","first-page":"S486","DOI":"10.1016\/j.ajog.2016.11.758","article-title":"Cost-effectiveness of exercise for the prevention of preeclampsia and gestational diabetes in normal weight women","volume":"216","author":"Savitsky","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"key2026062913240900_ref115-bib115","first-page":"S260","article-title":"Cost-effectiveness of exercise for the prevention of preeclampsia and gestational diabetes in obese women","volume":"216","author":"Savitsky","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"key2026062913240900_ref116-bib116","doi-asserted-by":"crossref","first-page":"116S","DOI":"10.1097\/01.AOG.0000514613.53010.ad","article-title":"Expectant management vs. induction of labor in women with severe proteinuria in preeclampsia","volume":"129","author":"Speranza","year":"2017","journal-title":"Obstet Gynecol"},{"key":"key2026062913240900_ref117-bib117","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s12471-015-0760-z","article-title":"Yearly hypertension screening in women with a history of pre-eclampsia: a cost-effectiveness analysis","volume":"23","author":"Drost","year":"2015","journal-title":"Neth Heart J"},{"key":"key2026062913240900_ref118-bib118","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijoa.2019.05.010","article-title":"Epidemiology of obstetric critical illness","volume":"40","author":"Einav","year":"2019","journal-title":"Int J Obstet Anesth"},{"key":"key2026062913240900_ref119-bib119","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12962-016-0062-3","article-title":"Optimizing treatment for the prevention of pre-eclampsia\/eclampsia in Nepal: is calcium supplementation during pregnancy cost-effective?","volume":"14","author":"Feldhaus","year":"2016","journal-title":"Cost Eff Resour Alloc"},{"key":"key2026062913240900_ref120-bib120","doi-asserted-by":"crossref","first-page":"e0180929","DOI":"10.1371\/journal.pone.0180929","article-title":"The cost effectiveness of a quality improvement program to reduce maternal and fetal mortality in a regional referral hospital in Accra, Ghana","volume":"12","author":"Goodman","year":"2017","journal-title":"PLOS ONE"},{"key":"key2026062913240900_ref121-bib121","doi-asserted-by":"crossref","first-page":"590.e1","DOI":"10.1016\/j.ajog.2019.02.017","article-title":"Induction of labor at 39 weeks of gestation versus expectant management for low-risk nulliparous women: a cost-effectiveness analysis","volume":"220","author":"Hersh","year":"2019","journal-title":"Am J Obstet Gynecol"},{"key":"key2026062913240900_ref122-bib122","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1177\/2047487319898021","article-title":"Impact of preventive screening and lifestyle interventions in women with a history of preeclampsia: a micro-simulation study","volume":"27","author":"Lagerweij","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"key2026062913240900_ref123-bib123","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.deveng.2017.06.002","article-title":"Cost effectiveness of medical devices to diagnose pre-eclampsia in low-resource settings","volume":"2","author":"McLaren","year":"2017","journal-title":"Dev Eng"},{"key":"key2026062913240900_ref124-bib124","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1093\/heapol\/czz034","article-title":"A cost-effectiveness analysis of maternal and neonatal health interventions in Ethiopia","volume":"34","author":"Memirie","year":"2019","journal-title":"Health Policy Plan"},{"key":"key2026062913240900_ref125-bib125","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1161\/HYPERTENSIONAHA.118.11718","article-title":"Preeclampsia prevention using routine versus screening test-indicated aspirin in low-risk women","volume":"72","author":"Mone","year":"2018","journal-title":"Hypertension"},{"key":"key2026062913240900_ref126-bib126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta21610","article-title":"Spot protein-creatinine ratio and spot albumin-creatinine ratio in the assessment of pre-eclampsia: a diagnostic accuracy study with decision-analytic model-based economic evaluation and acceptability analysis","volume":"21","author":"Waugh","year":"2017","journal-title":"Health Technol Assess"},{"key":"key2026062913240900_ref127-bib127","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/AOG.0000000000001115","article-title":"A cost-benefit analysis of low-dose aspirin prophylaxis for the prevention of preeclampsia in the United States","volume":"126","author":"Werner","year":"2015","journal-title":"Obstet Gynecol"},{"key":"key2026062913240900_ref128-bib128","first-page":"73","article-title":"Taking into account the quality of life of pregnant women in general practice","volume":"124","author":"Lagadec","year":"2016","journal-title":"Exercer"},{"key":"key2026062913240900_ref129-bib129","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/aogs.13068","article-title":"\u2018The burden of pregnancy\u2019; heavier for the heaviest? The changes in health related quality of life (HRQoL) assessed by the 15D instrument during pregnancy and postpartum in different body mass index groups: a longitudinal survey","volume":"96","author":"Sahrakorpi","year":"2017","journal-title":"Acta Obstet Gynecol Scand"},{"key":"key2026062913240900_ref130-bib130","doi-asserted-by":"crossref","first-page":"e0194999","DOI":"10.1371\/journal.pone.0194999","article-title":"Trajectories and predictors of women\u2019s health-related quality of life during pregnancy: a large longitudinal cohort study","volume":"13","author":"Bai","year":"2018","journal-title":"PLOS ONE"},{"key":"key2026062913240900_ref131-bib131","doi-asserted-by":"crossref","first-page":"e1951","DOI":"10.6061\/clinics\/2020\/e1951","article-title":"Multiprofessional care promotes of quality of life in pregnant women with preeclampsia: a cross-sectional study","volume":"75","author":"Machado","year":"2020","journal-title":"Clinics (Sao Paulo)"},{"key":"key2026062913240900_ref133-bib133","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1001\/archpediatrics.2008.1","article-title":"Parental tolerance of false-positive newborn screening results","volume":"162","author":"Prosser","year":"2008","journal-title":"Arch Pediatr Adolesc Med"},{"key":"key2026062913240900_ref134-bib134","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jpsychores.2007.06.003","article-title":"Psychometric evaluation of health-related quality of life measures in women after different types of delivery","volume":"63","author":"Jansen","year":"2007","journal-title":"J Psychosom Res"},{"key":"key2026062913240900_ref135-bib135","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3109\/10641955.2010.486458","article-title":"Health-related quality of life after induction of labor versus expectant monitoring in gestational hypertension or preeclampsia at term","volume":"30","author":"Bijlenga","year":"2011","journal-title":"Hypertens Pregnancy"},{"key":"key2026062913240900_ref136-bib136","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta23130","article-title":"Three biomarker tests to help diagnose preterm labour: a systematic review and economic evaluation","volume":"23","author":"Varley-Campbell","year":"2019","journal-title":"Health Technol Assess"},{"key":"key2026062913240900_ref137-bib137","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1524-4733.2010.00700.x","article-title":"Populating an economic model with health state utility values: moving toward better practice","volume":"13","author":"Ara","year":"2010","journal-title":"Value Health"},{"key":"key2026062913240900_ref138-bib138","doi-asserted-by":"crossref","first-page":"n1857","DOI":"10.1136\/bmj.n1857","article-title":"Placental growth factor in assessment of women with suspected pre-eclampsia to reduce maternal morbidity: a stepped wedge cluster randomised control trial (PARROT Ireland)","volume":"374","author":"Hayes-Ryan","year":"2021","journal-title":"BMJ"},{"key":"key2026062913240900_ref139-bib139","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1161\/CIRCULATIONAHA.113.003215","article-title":"Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study","volume":"128","author":"Chappell","year":"2013","journal-title":"Circulation"},{"key":"key2026062913240900_ref140-bib140","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/1471-0528.12259","article-title":"Cost and resource implications with serum angiogenic factor estimation in the triage of pre-eclampsia","volume":"120","author":"Schnettler","year":"2013","journal-title":"BJOG"},{"key":"key2026062913240900_ref141-bib141","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.preghy.2020.03.002","article-title":"Correlation of Kryptor and Elecsys (R) immunoassay sFlt-1\/PlGF ratio on early diagnosis of preeclampsia and fetal growth restriction: a case-control study","volume":"20","author":"Simon","year":"2020","journal-title":"Pregnancy Hypertens"},{"key":"key2026062913240900_ref142-bib142","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ajog.2020.11.007","article-title":"Performance of soluble fms-like tyrosine kinase-1-to-placental growth factor ratio of \u226585 for ruling in preeclampsia within 4 weeks","volume":"224","author":"Cerdeira","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"key2026062913240900_ref145-bib145","volume-title":"Drugs and Pharmaceutical Electronic Market Information Tool (eMIT)","author":"Department of Health and Social Care","year":"2020"},{"key":"key2026062913240900_ref146-bib146","volume-title":"British National Formulary","author":"Joint Formulary Committee","year":"2021"},{"key":"key2026062913240900_ref147-bib147","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S0140-6736(19)31963-4","article-title":"Planned early delivery or expectant management for late preterm pre-eclampsia (PHOENIX): a randomised controlled trial","volume":"394","author":"Chappell","year":"2019","journal-title":"Lancet"},{"key":"key2026062913240900_ref148-bib148","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1111\/1471-0528.13515","article-title":"Economic costs associated with moderate and late preterm birth: a prospective population-based study","volume":"122","author":"Khan","year":"2015","journal-title":"BJOG"},{"key":"key2026062913240900_ref149-bib149","volume-title":"Unit Costs of Health and Social Care 2020","author":"Curtis","year":"2020"},{"key":"key2026062913240900_ref150-bib150","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1469-8749.2008.03190.x","article-title":"Lifetime costs of cerebral palsy","volume":"51","author":"Kruse","year":"2009","journal-title":"Dev Med Child Neurol"},{"key":"key2026062913240900_ref151-bib151","volume-title":"Deaths Registered in England and Wales: 2015","author":"Office for National Statistics","year":"2015"},{"key":"key2026062913240900_ref152-bib152","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/1471-0528.17296","article-title":"Effect of race on the measurement of angiogenic factors for prediction and diagnosis of pre-eclampsia","volume":"130","author":"Wright","year":"2023","journal-title":"BJOG"},{"key":"key2026062913240900_ref153-bib153","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0140-6736(23)02357-7","article-title":"Repeat placental growth factor-based testing in women with suspected preterm pre-eclampsia (PARROT-2): a multicentre, parallel-group, superiority, randomised controlled trial","volume":"403","author":"Hurrell","year":"2024","journal-title":"Lancet"},{"key":"key2026062913240900_ref154-bib154","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/uog.20117","article-title":"Prediction of pre-eclampsia: review of reviews","volume":"54","author":"Townsend","year":"2019","journal-title":"Ultrasound Obstet Gynecol"},{"key":"key2026062913240900_ref155-bib155","doi-asserted-by":"crossref","first-page":"S407","DOI":"10.1016\/j.ajog.2019.11.654","article-title":"639: sFlt-1-:PLGF versus standard evaluation to predict outcome and time to delivery in suspected late-preterm preeclampsia","volume":"222","author":"Adami","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"key2026062913240900_ref156-bib156","first-page":"268A","article-title":"Plgf and sFlt-1 predict preeclampsia and latency to delivery in patients undergoing evaluation for hypertension","volume":"26","author":"Adami","year":"2019","journal-title":"Reprod Sci"},{"key":"key2026062913240900_ref157-bib157","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jash.2014.11.008","article-title":"Diagnosis of preeclampsia with soluble Fms-like tyrosine kinase 1\/placental growth factor ratio: an inter\u2013assay comparison","volume":"9","author":"Andersen","year":"2015","journal-title":"J Am Soc Hypertens"},{"key":"key2026062913240900_ref158-bib158","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3109\/10641955.2016.1167219","article-title":"Prediction of preeclampsia with angiogenic biomarkers: results from the prospective Odense Child Cohort","volume":"35","author":"Andersen","year":"2016","journal-title":"Hypertens Pregnancy"},{"key":"key2026062913240900_ref159-bib159","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/uog.17403","article-title":"Repeat measurements of uterine artery pulsatility index, mean arterial pressure and serum placental growth factor at 12, 22 and 32 weeks in prediction of pre-eclampsia","volume":"50","author":"Andrietti","year":"2017","journal-title":"Ultrasound Obstet Gynecol"},{"key":"key2026062913240900_ref160-bib160","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/uog.15812","article-title":"Competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 35\u201337 weeks\u2019 gestation","volume":"48","author":"Andrietti","year":"2016","journal-title":"Ultrasound Obstet Gynecol"},{"key":"key2026062913240900_ref161-bib161","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s00404-016-4128-4","article-title":"Using the angiogenic factors sFlt-1 and PlGF with Doppler ultrasound of the uterine artery for confirming preeclampsia","volume":"294","author":"Bahlmann","year":"2016","journal-title":"Arch Gynecol Obstet"},{"key":"key2026062913240900_ref162-bib162","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1515\/jpm-2019-0019","article-title":"The sFlt-1\/PlGF ratio values within the <38, 38\u201385 and >85 brackets as compared to perinatal outcomes","volume":"47","author":"Bednarek-Jedrzejek","year":"2019","journal-title":"J Perinat Med"},{"key":"key2026062913240900_ref163-bib163","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.preghy.2018.04.010","article-title":"Predictive value of sFlt-1, PlGF, sFlt-1\/PlGF ratio and PAPP-A for late-onset preeclampsia and IUGR between 32 and 37weeks of pregnancy","volume":"12","author":"Birdir","year":"2018","journal-title":"Pregnancy Hypertens"},{"key":"key2026062913240900_ref164-bib164","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.placenta.2019.08.083","article-title":"Midpregnancy testing for soluble fms-like tyrosine kinase 1 (sFlt-1) and placental growth factor (PlGF): an inter-assay comparison of three automated immunoassay platforms","volume":"86","author":"Black","year":"2019","journal-title":"Placenta"},{"key":"key2026062913240900_ref165-bib165","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.preghy.2019.03.009","article-title":"Midpregnancy prediction of pre-eclampsia using serum biomarkers sFlt-1 and PlGF","volume":"16","author":"Black","year":"2019","journal-title":"Pregnancy Hypertens"},{"key":"key2026062913240900_ref166-bib166","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/ajo.13113","article-title":"Prediction of preterm pre-eclampsia at midpregnancy using a multivariable screening algorithm","volume":"60","author":"Black","year":"2020","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"key2026062913240900_ref167-bib167","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3343\/alm.2018.38.2.95","article-title":"Evaluation of sFlt-1\/PlGF ratio for predicting and improving clinical management of pre-eclampsia: experience in a specialized perinatal care center","volume":"38","author":"Caillon","year":"2018","journal-title":"Ann Lab Med"},{"key":"key2026062913240900_ref168-bib168","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3109\/14767058.2016.1168800","article-title":"PlGF in a clinical setting of pregnancies at risk of preeclampsia and\/or intrauterine growth restriction","volume":"30","author":"Cetin","year":"2017","journal-title":"J Matern Fetal Neonatal Med"},{"key":"key2026062913240900_ref169-bib169","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.3109\/14767058.2015.1048431","article-title":"The use of angiogenic biomarkers in maternal blood to identify which SGA fetuses will require a preterm delivery and mothers who will develop pre-eclampsia","volume":"29","author":"Chaiworapongsa","year":"2016","journal-title":"J Matern Fetal Neonatal Med"},{"key":"key2026062913240900_ref170-bib170","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.pedneo.2016.10.005","article-title":"The sFlt-1\/PlGF ratio as a predictor for poor pregnancy and neonatal outcomes","volume":"58","author":"Chang","year":"2017","journal-title":"Pediatr Neonatol"},{"key":"key2026062913240900_ref171-bib171","first-page":"45","article-title":"Soluble fms-like tyrosine kinase-1 and placental growth factor in Chinese pregnant women during second and third trimesters","volume":"24","author":"Cheng","year":"2018","journal-title":"Hong Kong Med J"},{"key":"key2026062913240900_ref172-bib172","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.preghy.2017.12.002","article-title":"Soluble fms-like tyrosine kinase-1, placental growth factor and their ratio as a predictor for pre-eclampsia in East Asians","volume":"11","author":"Cheng","year":"2018","journal-title":"Pregnancy Hypertens"},{"key":"key2026062913240900_ref173-bib173","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7754\/Clin.Lab.2020.200117","article-title":"Preeclampsia screening using the ratio of soluble FMS-like tyrosine kinase-1 to placental growth factor during pregnancy in pregnant Korean women","volume":"66","author":"Choi","year":"2020","journal-title":"Clin Lab"},{"key":"key2026062913240900_ref174-bib174","doi-asserted-by":"crossref","first-page":"584.e1","DOI":"10.1016\/j.ajog.2019.01.235","article-title":"Prediction of imminent preeclampsia at 35\u201337 weeks gestation","volume":"220","author":"Ciobanu","year":"2019","journal-title":"Am J Obstet Gynecol"},{"key":"key2026062913240900_ref175-bib175","first-page":"S25","article-title":"Predictive SFLT-1\/PLGF cut-off value in patients with pre-eclampsia at the end of pregnancy with or without pre-eclampsia at the time of first admission","volume":"42","author":"Contino","year":"2018","journal-title":"Biochim Clin"},{"key":"key2026062913240900_ref176-bib176","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1161\/HYPERTENSIONAHA.120.15146","article-title":"Prediction of preeclampsia-related adverse outcomes with the sFlt-1 (soluble FMS-like tyrosine kinase 1)\/PlGF (placental growth factor)-ratio in the clinical routine: a real-world study","volume":"77","author":"Dr\u00f6ge","year":"2021","journal-title":"Hypertension"},{"key":"key2026062913240900_ref177-bib177","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/aogs.13818","article-title":"Diagnostic accuracy of repeat placental growth factor measurements in women with suspected preeclampsia: a case series study","volume":"99","author":"Duhig","year":"2020","journal-title":"Acta Obstet Gynecol Scand"},{"key":"key2026062913240900_ref178-bib178","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.preghy.2020.01.009","article-title":"Retrospective evaluation of established cut-off values for the sFlt-1\/PlGF ratio for predicting imminent delivery in preeclampsia patients","volume":"19","author":"Enengl","year":"2020","journal-title":"Pregnancy Hypertens"},{"key":"key2026062913240900_ref179-bib179","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1161\/HYPERTENSIONAHA.117.10314","article-title":"Neurofilament as neuronal injury blood marker in preeclampsia","volume":"71","author":"Evers","year":"2018","journal-title":"Hypertension"},{"key":"key2026062913240900_ref180-bib180","first-page":"S258","article-title":"Performance evaluation of the ADVIA centaur PlGF and sFlt-1 assays","volume":"63","author":"Frenna","year":"2017","journal-title":"Clin Chem"},{"key":"key2026062913240900_ref181-bib181","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S2352-4642(18)30129-9","article-title":"Screening for fetal growth restriction using ultrasound and the sFLT1\/PlGF ratio in nulliparous women: a prospective cohort study","volume":"2","author":"Gaccioli","year":"2018","journal-title":"Lancet Child Adolesc Health"},{"key":"key2026062913240900_ref182-bib182","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1080\/14767058.2020.1792878","article-title":"Placental growth factor as a predictive marker of preeclampsia-PREBIO study-PREeclampsia BIOchemical study","volume":"35","author":"Giardini","year":"2022","journal-title":"J Matern Fetal Neonatal Med"},{"key":"key2026062913240900_ref183-bib183","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000370332","article-title":"Use of placental growth factor and uterine artery Doppler pulsatility index in pregnancies involving intrauterine fetal growth restriction or preeclampsia to predict perinatal outcomes","volume":"80","author":"Gomez-Roig","year":"2015","journal-title":"Gynecol Obstet Invest"},{"key":"key2026062913240900_ref184-bib184","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00404-018-4840-3","article-title":"sFlt-1\/PlGF ratio for the prediction of the time of delivery","volume":"298","author":"Graupner","year":"2018","journal-title":"Arch Gynecol Obstet"},{"key":"key2026062913240900_ref185-bib185","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/uog.17490","article-title":"Predicting delivery of a small-for-gestational-age infant and adverse perinatal outcome in women with suspected pre-eclampsia","volume":"51","author":"Griffin","year":"2018","journal-title":"Ultrasound Obstet Gynecol"},{"key":"key2026062913240900_ref186-bib186","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.preghy.2020.04.004","article-title":"Angiogenic factor abnormalities and risk of peripartum complications and prematurity among urban predominantly obese parturients with chronic hypertension","volume":"20","author":"Heimberger","year":"2020","journal-title":"Pregnancy Hypertens"},{"key":"key2026062913240900_ref187-bib187","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/uog.18894","article-title":"Longitudinal change of sFlt-1\/PlGF ratio in singleton pregnancy with early-onset fetal growth restriction","volume":"52","author":"Herraiz","year":"2018","journal-title":"Ultrasound Obstet Gynecol"},{"key":"key2026062913240900_ref188-bib188","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.preghy.2018.06.017","article-title":"Clinical implementation of the sFlt-1\/PlGF ratio to identify preeclampsia and fetal growth restriction: a prospective cohort study","volume":"13","author":"Herraiz","year":"2018","journal-title":"Pregnancy Hypertens"},{"key":"key2026062913240900_ref189-bib189","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.preghy.2018.10.004","article-title":"Serum soluble LIGHT in the early third trimester as a novel biomarker for predicting late-onset preeclampsia","volume":"14","author":"Hirashima","year":"2018","journal-title":"Pregnancy Hypertens"},{"key":"key2026062913240900_ref190-bib190","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.preghy.2017.08.003","article-title":"An intermediate sFlt-1\/PlGF ratio indicates an increased risk for adverse pregnancy outcome","volume":"10","author":"Hoffmann","year":"2017","journal-title":"Pregnancy Hypertens"},{"key":"key2026062913240900_ref191-bib191","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/jp.2015.170","article-title":"Analysis of changes in maternal circulating angiogenic factors throughout pregnancy for the prediction of preeclampsia","volume":"36","author":"Honigberg","year":"2016","journal-title":"J Perinatol"},{"key":"key2026062913240900_ref192-bib192","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3389\/fmed.2018.00325","article-title":"Diagnostic accuracy of different soluble fms-like tyrosine kinase 1 and placental growth factor cut-off values in the assessment of preterm and term preeclampsia: a gestational age matched case-control study","volume":"5","author":"Huhn","year":"2018","journal-title":"Front Med"},{"key":"key2026062913240900_ref193-bib193","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.preghy.2019.04.006","article-title":"Prediction of preeclampsia using combination of biomarkers at 18\u201323 weeks of gestation: a nested case-control study","volume":"17","author":"Jadli","year":"2019","journal-title":"Pregnancy Hypertens"},{"key":"key2026062913240900_ref194-bib194","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.preghy.2020.09.007","article-title":"Role of sFlt-1\/PIGF ratio and uterine Doppler in pregnancies with chronic kidney disease suspected with pre-eclampsia or HELLP syndrome","volume":"22","author":"Karge","year":"2020","journal-title":"Pregnancy Hypertens"},{"key":"key2026062913240900_ref195-bib195","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.preghy.2021.02.003","article-title":"Prediction of adverse perinatal outcome and the mean time until delivery in twin pregnancies with suspected pre-eclampsia using sFlt-1\/PIGF ratio","volume":"24","author":"Karge","year":"2021","journal-title":"Pregnancy Hypertens"},{"key":"key2026062913240900_ref196-bib196","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/uog.17561","article-title":"Prediction of severe pre-eclampsia\/HELLP syndrome by combination of sFlt-1, CT-pro-ET-1 and blood pressure: exploratory study","volume":"51","author":"Lind Malte","year":"2018","journal-title":"Ultrasound Obstet Gynecol"},{"key":"key2026062913240900_ref197-bib197","doi-asserted-by":"crossref","first-page":"6270187","DOI":"10.1155\/2019\/6270187","article-title":"Maternal serum angiogenic factor sFlt-1 to PlGF ratio in preeclampsia: a useful marker for differential diagnosis and prognosis evaluation in Chinese women","volume":"2019","author":"Lou","year":"2019","journal-title":"Dis Markers"},{"key":"key2026062913240900_ref198-bib198","doi-asserted-by":"crossref","first-page":"45","DOI":"10.22159\/ijcpr.2020v12i3.38305","article-title":"The role of predictor placental growth factor, soluble endoglin, soluble-fms-like-tyrosine kinase-1 and pulsatility uterine arterial index to predict the early onset of preeclampsia","volume":"12","author":"Lubis","year":"2020","journal-title":"Int J Curr Pharm Res"},{"key":"key2026062913240900_ref199-bib199","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.3889\/oamjms.2019.154","article-title":"The role of placental growth factor, soluble endoglin, and uterine artery diastolic notch to predict the early onset of preeclampsia","volume":"7","author":"Lubis","year":"2019","journal-title":"Open Access Maced J Med Sci"},{"key":"key2026062913240900_ref200-bib200","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1186\/s12884-018-1992-x","article-title":"Assessing the sensitivity of placental growth factor and soluble fms-like tyrosine kinase 1 at 36 weeks\u2019 gestation to predict small-for-gestational-age infants or late-onset preeclampsia: a prospective nested case-control study","volume":"18","author":"MacDonald","year":"2018","journal-title":"BMC Pregnancy Childbirth"},{"key":"key2026062913240900_ref201-bib201","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s13224-015-0793-7","article-title":"A prospective study of placental growth factor assay as a novel biomarker in predicting early-onset preeclampsia in high-risk patients","volume":"66","author":"Mathur","year":"2016","journal-title":"J Obstet Gynaecol India"},{"key":"key2026062913240900_ref202-bib202","first-page":"1583790","article-title":"The importance of PlGF-quick tests for the diagnosis of preeclampsia in clinical practice","volume":"76","author":"Menke","year":"2016","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"key2026062913240900_ref203-bib203","first-page":"473","article-title":"The correlation between markers of systemic inflammation and angiogenic markers in pre-eclampsia","volume":"119","author":"Mihalceanu","year":"2015","journal-title":"Rev Med Chir Soc Med Nat Iasi"},{"key":"key2026062913240900_ref204-bib204","first-page":"269A","article-title":"Validation of SFLT1\/PLGF ratio to rule out preeclampsia with severe features","volume":"27","author":"Mueller","year":"2020","journal-title":"Reprod Sci"},{"key":"key2026062913240900_ref205-bib205","doi-asserted-by":"crossref","first-page":"S200","DOI":"10.1016\/j.ajog.2017.10.255","article-title":"Maternal serum glycosylated fibronectin as a short-term predictor of preeclampsia: a rapid point-of-care test for rule-in or rule-out preeclampsia","volume":"218","author":"Nagalla","year":"2018","journal-title":"Am J Obstet Gynecol"},{"key":"key2026062913240900_ref206-bib206","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1111\/1471-0528.16323","article-title":"Glycosylated fibronectin point-of-care test for diagnosis of pre-eclampsia in a low-resource setting: a prospective Southeast Asian population study","volume":"127","author":"Nagalla","year":"2020","journal-title":"BJOG"},{"key":"key2026062913240900_ref207-bib207","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/14767058.2017.1373760","article-title":"Evaluation of agreement of placental growth factor (PlGF) tests and the soluble FMS-like tyrosine kinase 1 (sFlt-1)\/PlGF ratio, comparison of predictive accuracy for pre-eclampsia, and relation to uterine artery Doppler and response to aspirin","volume":"32","author":"Navaratnam","year":"2019","journal-title":"J Matern Fetal Neonatal Med"},{"key":"key2026062913240900_ref208-bib208","first-page":"46","article-title":"Agreement between different PlGF tests and the sFlt-1\/PlGF ratio for prediction of pre-eclampsia and potential to predict fetal growth restriction in high risk populations","volume":"126","author":"Navaratnam","year":"2019","journal-title":"BJOG"},{"key":"key2026062913240900_ref209-bib209","doi-asserted-by":"crossref","first-page":"e018219","DOI":"10.1161\/JAHA.120.018219","article-title":"PAPP-A2 and inhibin A as novel predictors for pregnancy complications in women with suspected or confirmed preeclampsia","volume":"9","author":"Neuman","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"key2026062913240900_ref210-bib210","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.preghy.2020.11.011","article-title":"Angiogenic markers during preeclampsia: are they associated with hypertension 1 year postpartum?","volume":"23","author":"Neuman","year":"2021","journal-title":"Pregnancy Hypertens"},{"key":"key2026062913240900_ref211-bib211","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.preghy.2018.07.008","article-title":"Predictive value of the sFlt-1 and PlGF in women at risk for preeclampsia in the south of Vietnam","volume":"14","author":"Nguyen","year":"2018","journal-title":"Pregnancy Hypertens"},{"key":"key2026062913240900_ref212-bib212","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/jmwh.12496_1","article-title":"Prediction of women at low risk for preeclampsia with Sflt-1:P1gf ratio","volume":"61","author":"Niemczyk","year":"2016","journal-title":"J Midwifery Womens Health"},{"key":"key2026062913240900_ref213-bib213","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1080\/14767058.2016.1182975","article-title":"Maternal plasma concentrations of the placental specific sFLT-1 variant, sFLT-1 e15a, in fetal growth restriction and preeclampsia","volume":"30","author":"Palmer","year":"2017","journal-title":"J Matern Fetal Neonatal Med"},{"key":"key2026062913240900_ref214-bib214","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/jpc.14409_109","article-title":"Placental specific sFLT1: use in the prediction or diagnosis of preeclampsia","volume":"55","author":"Palmer","year":"2019","journal-title":"J Paediatr Child Health"},{"key":"key2026062913240900_ref215-bib215","doi-asserted-by":"crossref","first-page":"S298","DOI":"10.1016\/j.ajog.2018.11.463","article-title":"442: Plasma placental growth factor and the risk of adverse perinatal outcome","volume":"220","author":"Parchem","year":"2019","journal-title":"Am J Obstet Gynecol"},{"key":"key2026062913240900_ref216-bib216","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1097\/AOG.0000000000003694","article-title":"Placental growth factor and the risk of adverse neonatal and maternal outcomes","volume":"135","author":"Parchem","year":"2020","journal-title":"Obstet Gynecol"},{"key":"key2026062913240900_ref217-bib217","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/uog.17373","article-title":"sFlt-1\/PlGF for prediction of early-onset pre-eclampsia: STEPS (Study of Early Pre-eclampsia in Spain)","volume":"50","author":"Perales","year":"2017","journal-title":"Ultrasound Obstet Gynecol"},{"key":"key2026062913240900_ref218-bib218","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1161\/HYPERTENSIONAHA.118.12205","article-title":"Angiogenic factor estimation as a warning sign of preeclampsia-related peripartum morbidity among hospitalized patients","volume":"73","author":"Perdigao","year":"2019","journal-title":"Hypertension"},{"key":"key2026062913240900_ref219-bib219","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1136\/bmjebm-2019-111228","article-title":"Placental growth factor testing to assess women with suspected pre-eclampsia","volume":"25","author":"Pluddemann","year":"2020","journal-title":"BMJ Evid Based Med"},{"key":"key2026062913240900_ref220-bib220","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1080\/14767058.2017.1378325","article-title":"Angiogenic factors for prediction of preeclampsia and intrauterine growth restriction onset in high-risk women: AngioPred study","volume":"32","author":"Raia-Barjat","year":"2019","journal-title":"J Matern Fetal Neonatal Med"},{"key":"key2026062913240900_ref221-bib221","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1161\/HYPERTENSIONAHA.116.08641","article-title":"Angiogenic proteins: can these biomarkers help to prevent maternal deaths related to preeclampsia?","volume":"69","author":"Rana","year":"2017","journal-title":"Hypertension"},{"key":"key2026062913240900_ref222-bib222","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1093\/jalm\/jfaa054","article-title":"Single-tube multimarker assay for estimating the risk to develop preeclampsia","volume":"5","author":"Ratnik","year":"2020","journal-title":"J Appl Lab Med"},{"key":"key2026062913240900_ref223-bib223","first-page":"29","article-title":"New biomarkers for pregnancy","volume":"95","author":"Ratnik","year":"2016","journal-title":"Eesti Arst"},{"key":"key2026062913240900_ref224-bib224","doi-asserted-by":"crossref","first-page":"S145","DOI":"10.1016\/j.ekir.2019.05.372","article-title":"SAT-327 alexis: the application of sFlt-1:PLlGF ratio to exclude pre-eclampsia study","volume":"4","author":"Roche","year":"2019","journal-title":"Kidney Int Rep"},{"key":"key2026062913240900_ref225-bib225","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.preghy.2018.01.008","article-title":"The role of angiogenic biomarkers and uterine artery Doppler in pregnant women with systemic lupus erythematosus or antiphospholipid syndrome","volume":"11","author":"Rodriguez-Almaraz","year":"2018","journal-title":"Pregnancy Hypertens"},{"key":"key2026062913240900_ref226-bib226","doi-asserted-by":"crossref","first-page":"127083","DOI":"10.1155\/2015\/127083","article-title":"Is it possible to differentiate chronic kidney disease and preeclampsia by means of new and old biomarkers? A prospective study","volume":"2015","author":"Rolfo","year":"2015","journal-title":"Dis Markers"},{"key":"key2026062913240900_ref227-bib227","first-page":"72","article-title":"Value of a placental-specific to total soluble fms-like tyrosine kinase 1 ratio in women with pre-eclampsia","volume":"59","author":"Rowson","year":"2019","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"key2026062913240900_ref228-bib228","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1055\/s-0040-1713916","article-title":"Evaluation of angiogenic factors (PlGF and sFlt-1) in pre-eclampsia diagnosis","volume":"42","author":"Sa","year":"2020","journal-title":"Rev Bras Ginecol Obstet"},{"key":"key2026062913240900_ref229-bib229","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1515\/cclm-2017-0443","article-title":"Use of the sFlt-1\/PlGF ratio to rule out preeclampsia requiring delivery in women with suspected disease: is the evidence reproducible?","volume":"56","author":"Sabria","year":"2018","journal-title":"Clin Chem Lab Med"},{"key":"key2026062913240900_ref230-bib230","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/uog.19040","article-title":"Addition of N-terminal pro-B natriuretic peptide to soluble fms-like tyrosine kinase-1\/placental growth factor ratio > 38 improves prediction of pre-eclampsia requiring delivery within 1 week: a longitudinal cohort study","volume":"51","author":"Sabria","year":"2018","journal-title":"Ultrasound Obstet Gynecol"},{"key":"key2026062913240900_ref231-bib231","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1002\/uog.23142","article-title":"Prediction of pre-eclampsia-related complications in women with suspected\/confirmed pre-eclampsia: development and internal validation of a clinical prediction model","volume":"58","author":"Saleh","year":"2021","journal-title":"Ultrasound Obstet Gynecol"},{"key":"key2026062913240900_ref232-bib232","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/uog.17547","article-title":"Soluble fms-like tyrosine kinase-1 and placental growth factor kinetics during and after pregnancy in women with suspected or confirmed pre-eclampsia","volume":"51","author":"Saleh","year":"2018","journal-title":"Ultrasound Obstet Gynecol"},{"key":"key2026062913240900_ref233-bib233","doi-asserted-by":"crossref","first-page":"e287","DOI":"10.1097\/01.hjh.0000523838.66141.84","article-title":"The evolution of SFLT-1\/PLGF ratio during pregnancy in women with (suspected) preeclampsia","volume":"35","author":"Saleh","year":"2017","journal-title":"J Hypertens"},{"key":"key2026062913240900_ref234-bib234","article-title":"The sFlt-1\/PlGF ratio associates with prolongation of pregnancy","volume":"66","author":"Saleh","year":"2015","journal-title":"Hypertens Conf"},{"key":"key2026062913240900_ref235-bib235","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1097\/01.hjh.0000491506.02314.76","article-title":"Angiogenic imbalanced preeclampsia versus clinical preeclampsia","volume":"34","author":"Saleh","year":"2016","journal-title":"J Hypertens"},{"key":"key2026062913240900_ref236-bib236","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.preghy.2016.08.126","article-title":"Predictive value of repetitive measurement of sFlt-1:PLGF ratio in women with (suspected) preeclampsia","volume":"6","author":"Saleh","year":"2016","journal-title":"Pregnancy Hypertens"},{"key":"key2026062913240900_ref237-bib237","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1161\/HYPERTENSIONAHA.117.09913","article-title":"Angiogenic markers predict pregnancy complications and prolongation in preeclampsia: continuous versus cutoff values","volume":"70","author":"Saleh","year":"2017","journal-title":"Hypertension"},{"key":"key2026062913240900_ref238-bib238","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.preghy.2016.08.028","article-title":"The added value of the biomarkers sFlt-1, PlGF and their ratio on prediction of prolongation of pregnancy and maternal and fetal complications in (suspected) preeclampsia","volume":"6","author":"Saleh","year":"2016","journal-title":"Pregnancy Hypertens"},{"key":"key2026062913240900_ref239-bib239","doi-asserted-by":"crossref","first-page":"iii463","DOI":"10.1093\/ndt\/gfx163.MP101","article-title":"A comparison of circulating angiogenic factors with routine protein analytes as markers of preeclampsia in healthy women","volume":"32","author":"Sarween","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"key2026062913240900_ref240-bib240","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.preghy.2019.01.012","article-title":"Angiogenic factors and uterine artery Doppler in predicting preeclampsia and associated adverse outcomes in a tertiary hospital in south India","volume":"16","author":"Sebastian","year":"2019","journal-title":"Pregnancy Hypertens"},{"key":"key2026062913240900_ref241-bib241","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.preghy.2020.07.007","article-title":"sFlt-1\/PlGF ratio for the prediction of delivery within 48 hours and adverse outcomes in expectantly managed early-onset preeclampsia","volume":"22","author":"Simon","year":"2020","journal-title":"Pregnancy Hypertens"},{"key":"key2026062913240900_ref242-bib242","first-page":"2396","article-title":"Placental growth factor testing for faster preeclampsia diagnosis","volume":"321","author":"Slomski","year":"2019","journal-title":"JAMA"},{"key":"key2026062913240900_ref243-bib243","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.preghy.2016.08.047","article-title":"Prediction of preeclampsia using the sFlt-1:PLGF ratio: a prospective cohort study of unselected nulliparous women","volume":"6","author":"Smith","year":"2016","journal-title":"Pregnancy Hypertens"},{"key":"key2026062913240900_ref244-bib244","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1161\/HYPERTENSIONAHA.116.08620","article-title":"Prediction of preeclampsia using the soluble fms-like tyrosine kinase 1 to placental growth factor ratio: a prospective cohort study of unselected nulliparous women","volume":"69","author":"Sovio","year":"2017","journal-title":"Hypertension"},{"key":"key2026062913240900_ref245-bib245","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3109\/10641955.2016.1141214","article-title":"A comparison of the diagnostic utility of the sFlt-1\/PlGF ratio versus PlGF alone for the detection of preeclampsia\/HELLP syndrome","volume":"35","author":"Stepan","year":"2016","journal-title":"Hypertens Pregnancy"},{"key":"key2026062913240900_ref246-bib246","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.preghy.2018.01.001","article-title":"An sFlt-1:PlGF ratio of 655 is not a reliable cut-off value for predicting perinatal outcomes in women with preeclampsia","volume":"11","author":"Stolz","year":"2018","journal-title":"Pregnancy Hypertens"},{"key":"key2026062913240900_ref247-bib247","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.preghy.2020.05.013","article-title":"Evaluation of angiogenic factors in the decision to admit women with suspected preeclampsia","volume":"21","author":"Suresh","year":"2020","journal-title":"Pregnancy Hypertens"},{"key":"key2026062913240900_ref248-bib248","doi-asserted-by":"crossref","first-page":"1408390","DOI":"10.1080\/20013078.2017.1408390","article-title":"Extracellular vesicles yield predictive pre-eclampsia biomarkers","volume":"6","author":"Tan","year":"2017","journal-title":"J Extracell Vesicles"},{"key":"key2026062913240900_ref249-bib249","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jogoh.2017.10.007","article-title":"Angiogenic factors sFlt-1 and PlGF in preeclampsia: prediction of risk and prognosis in a high-risk obstetric population","volume":"47","author":"Tardif","year":"2018","journal-title":"J Gynecol Obstet Hum Reprod"},{"key":"key2026062913240900_ref252-bib252","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.preghy.2019.09.015","article-title":"Association of serum angiogenic factors with bronchopulmonary dysplasia: the ANGIODYS cohort study","volume":"18","author":"Torchin","year":"2019","journal-title":"Pregnancy Hypertens"},{"key":"key2026062913240900_ref253-bib253","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/uog.15816","article-title":"Maternal serum placental growth factor at 12, 22, 32 and 36 weeks\u2019 gestation in screening for pre-eclampsia","volume":"47","author":"Tsiakkas","year":"2016","journal-title":"Ultrasound Obstet Gynecol"},{"key":"key2026062913240900_ref254-bib254","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/uog.15817","article-title":"Maternal serum soluble fms-like tyrosine kinase-1 at 12, 22, 32 and 36 weeks\u2019 gestation in screening for pre-eclampsia","volume":"47","author":"Tsiakkas","year":"2016","journal-title":"Ultrasound Obstet Gynecol"},{"key":"key2026062913240900_ref255-bib255","doi-asserted-by":"crossref","first-page":"87.e1","DOI":"10.1016\/j.ajog.2016.02.016","article-title":"Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 30\u201334 weeks\u2019 gestation","volume":"215","author":"Tsiakkas","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"key2026062913240900_ref256-bib256","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/uog.14928","article-title":"Biophysical and biochemical markers at 30\u201334 weeks\u2019 gestation in the prediction of adverse perinatal outcome","volume":"47","author":"Valino","year":"2016","journal-title":"Ultrasound Obstet Gynecol"},{"key":"key2026062913240900_ref257-bib257","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/uog.15663","article-title":"Biophysical and biochemical markers at 35\u201337 weeks\u2019 gestation in the prediction of adverse perinatal outcome","volume":"47","author":"Valino","year":"2016","journal-title":"Ultrasound Obstet Gynecol"},{"key":"key2026062913240900_ref258-bib258","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.clinbiochem.2015.06.020","article-title":"Analytical evaluation of the novel soluble fms-like tyrosine kinase 1 and placental growth factor assays for the diagnosis of preeclampsia","volume":"48","author":"van Helden","year":"2015","journal-title":"Clin Biochem"},{"key":"key2026062913240900_ref259-bib259","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/uog.17451","article-title":"Re: screening for pre-eclampsia using sFlt-1\/PlGF ratio cut-off of 38 at 30\u201337 weeks\u2019 gestation","volume":"49","author":"Vatish","year":"2017","journal-title":"Ultrasound Obstet Gynecol"},{"key":"key2026062913240900_ref260-bib260","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/uog.19079","article-title":"Re: Addition of N-terminal pro-B natriuretic peptide to soluble fms-like tyrosine kinase-1\/placental growth factor ratio > 38 improves prediction of pre-eclampsia requiring delivery within 1 week: a longitudinal cohort study","volume":"51","author":"Verlohren","year":"2018","journal-title":"Ultrasound Obstet Gynecol"},{"key":"key2026062913240900_ref261-bib261","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1161\/HYPERTENSIONAHA.117.09256","article-title":"Angiogenic markers and cardiovascular indices in the prediction of hypertensive disorders of pregnancy","volume":"69","author":"Verlohren","year":"2017","journal-title":"Hypertension"},{"key":"key2026062913240900_ref262-bib262","doi-asserted-by":"crossref","first-page":"e015548","DOI":"10.1161\/JAHA.119.015548","article-title":"Maternal and perinatal outcomes associated with extremely high values for the sFlt-1 (soluble fms-like tyrosine kinase 1)\/PlGF (placental growth factor) ratio","volume":"9","author":"Villalain","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"key2026062913240900_ref263-bib263","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.preghy.2015.09.004","article-title":"Accuracy of angiogenic biomarkers at <20 weeks\u2019 gestation in predicting the risk of pre-eclampsia: a WHO multicentre study","volume":"5","author":"Widmer","year":"2015","journal-title":"Pregnancy Hypertens"},{"key":"key2026062913240900_ref264-bib264","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.preghy.2021.02.010","article-title":"Placental and endothelial biomarkers for the prediction of superimposed pre-eclampsia in chronic kidney disease","volume":"24","author":"Wiles","year":"2021","journal-title":"Pregnancy Hypertens"},{"key":"key2026062913240900_ref265-bib265","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/01.ogx.0000482523.79556.f6","article-title":"Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia","volume":"71","author":"Zeisler","year":"2016","journal-title":"Obstet Gynecol Surv"},{"key":"key2026062913240900_ref266-bib266","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.preghy.2015.12.002","article-title":"Extending the scope of pooled analyses of individual patient biomarker data from heterogeneous laboratory platforms and cohorts using merging algorithms","volume":"6","author":"Burke","year":"2016","journal-title":"Pregnancy Hypertens"},{"key":"key2026062913240900_ref267-bib267","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1515\/cclm-2018-1228","article-title":"Elecsys and Kryptor immunoassays for the measurement of sFlt-1 and PlGF to aid preeclampsia diagnosis: are they comparable?","volume":"57","author":"Stepan","year":"2019","journal-title":"Clin Chem Lab Med"},{"key":"key2026062913240900_ref268-bib268","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3109\/10641950902968635","article-title":"Predictive value of clinical and laboratory indices at first assessment in women referred with suspected gestational hypertension","volume":"29","author":"Anumba","year":"2010","journal-title":"Hypertens Pregnancy"},{"key":"key2026062913240900_ref269-bib269","volume-title":"2016\/2017 Reference Costs and Guidance","author":"NHS Improvement","year":"2017"},{"key":"key2026062913240900_ref270-bib270","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/uog.14799","article-title":"Implementation of the sFlt-1\/PlGF ratio for prediction and diagnosis of pre-eclampsia in singleton pregnancy: implications for clinical practice","volume":"45","author":"Stepan","year":"2015","journal-title":"Ultrasound Obstet Gynecol"},{"key":"key2026062913240900_ref271-bib271","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1701-2163(15)30588-0","article-title":"Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary","volume":"36","author":"Magee","year":"2014","journal-title":"J Obstet Gynaecol Can"},{"key":"key2026062913240900_ref273-bib273","author":"Italian Association of Preeclampsia (AIPE) Guideline.","year":"2013"},{"key":"key2026062913240900_ref274-bib274","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ijgo.2012.04.020","article-title":"A comparison of quality of life following spontaneous conception and assisted reproduction","volume":"118","author":"De Pascalis","year":"2012","journal-title":"Int J Gynaecol Obstet"},{"key":"key2026062913240900_ref275-bib275","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jpsychores.2005.02.018","article-title":"The factor structure of the SF-36 in early pregnancy","volume":"59","author":"Jomeen","year":"2005","journal-title":"J Psychosom Res"},{"key":"key2026062913240900_ref276-bib276","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s10995-008-0392-7","article-title":"Longitudinal study of depressive symptoms and health-related quality of life during pregnancy and after delivery: the Health Status in Pregnancy (HIP) study","volume":"13","author":"Setse","year":"2009","journal-title":"Matern Child Health J"},{"key":"key2026062913240900_ref277-bib277","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1007\/s11136-011-9891-x","article-title":"Maternal health-related quality of life after induction of labor or expectant monitoring in pregnancy complicated by intrauterine growth retardation beyond 36 weeks","volume":"20","author":"Bijlenga","year":"2011","journal-title":"Qual Life Res"},{"key":"key2026062913240900_ref278-bib278","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/j.1524-4733.2008.00352.x","article-title":"Deriving an algorithm to convert the eight mean SF-36 dimension scores into a mean EQ-5D preference-based score from published studies (where patient level data are not available)","volume":"11","author":"Ara","year":"2008","journal-title":"Value Health"},{"key":"key2026062913240900_ref279-bib279","doi-asserted-by":"crossref","first-page":"790474","DOI":"10.1155\/2013\/790474","article-title":"Use of herbal dietary supplement si-wu-tang and health-related quality of life in postpartum women: a population-based correlational study","volume":"2013","author":"Chang","year":"2013","journal-title":"Evid Based Complement Alternat Med"},{"key":"key2026062913240900_ref280-bib280","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ijnurstu.2009.06.002","article-title":"Use of Sheng-Hua-Tang and health-related quality of life in postpartum women: a population-based cohort study in Taiwan","volume":"47","author":"Chang","year":"2010","journal-title":"Int J Nurs Stud"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2051442","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/sites\/journalslibrary\/files\/journal_data\/HDST9104\/HDST9104.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2051442","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T07:58:24Z","timestamp":1782719904000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/HDST9104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":266,"alternative-id":["10.3310\/HDST9104"],"URL":"https:\/\/doi.org\/10.3310\/hdst9104","relation":{},"ISSN":["2046-4924"],"issn-type":[{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"},{"value":"09-2020","name":"contractual_start_date","label":"contractual_start_date","group":{"name":"article_history","label":"Article History"}},{"value":"02-2025","name":"editorial_review_begun","label":"editorial review begun","group":{"name":"article_history","label":"Article History"}},{"value":"09-2025","name":"accepted_for_publication","label":"Accepted for publication","group":{"name":"article_history","label":"Article History"}}]}}